Virion Therapeutics has reported encouraging safety outcomes from the first-in-human Phase IB clinical study of VRON-0200, a checkpoint modifier immunotherapy being analysed as a functional cure for chronic hepatitis B virus (HBV) infection.
The multicentre, open-label, dose-escalation, prime only, and prime plus boost therapeutic vaccination trials are designed to assess the therapy’s tolerability, safety, and immunological responses.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial included non-cirrhotic, Hepatitis B e antigen (HBeAg) positive or negative, chronic hepatitis B patients who are currently on nucleos(t)ide antiviral therapy and have HBV DNA levels below 40IU/mL and HBsAg levels under 500IU/mL.
Virion dosed the first patients in the trial last October.
This dose escalation study comprised two cohorts, with cohort one receiving a low dose of VRON-0200 and cohort two subjects being administered a high dose.
Subjects within each cohort are randomised to receive either an intramuscular injection as a prime vaccination only or as a prime and boost regimen.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to the initial results obtained from the first ten subjects, the immunotherapy was safe and well-tolerated without any significant adverse events reported.
Furthermore, no clinically relevant abnormalities were observed in laboratory tests, electrocardiograms (ECGs), or vital signs.
Preclinical data suggest that VRON-0200, through checkpoint modification, could amplify and enhance T cell responses, including those not normally activated during chronic HBV infection, thereby improving viral control.
Virion Therapeutics COO Dr Sue Currie said: “Finding a treatment for chronic HBV-infected patients will almost assuredly require an immune-based component to help control the infection.
“These VRON-0200 data—the first ever for a checkpoint modifier containing T cell vaccine of any kind—represent a critical first step in Virion’s mission to bring safe, well-tolerated, and easy-to-administer interferon-sparing functional cure immunotherapy to HBV-infected patients worldwide.
“We look forward to sharing additional safety and the first-ever immunogenicity data from this trial later this year.”
